CYCLERION THERAPEUTICS INC's ticker is CYCN and the CUSIP is 23255M105. A total of 44 filers reported holding CYCLERION THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $44 | -35.3% | 102,884 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $68 | -99.9% | 102,884 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $88,000 | +54.4% | 102,884 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $57,000 | -50.0% | 102,884 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $114,000 | -35.6% | 102,884 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $177,000 | -44.0% | 102,884 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $316,000 | -21.2% | 102,884 | 0.0% | 0.01% | -25.0% |
| Q2 2021 | $401,000 | +39.7% | 102,884 | 0.0% | 0.01% | +33.3% |
| Q1 2021 | $287,000 | -8.9% | 102,884 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $315,000 | -49.7% | 102,884 | 0.0% | 0.01% | -56.2% |
| Q3 2020 | $626,000 | +3.0% | 102,884 | 0.0% | 0.02% | -11.1% |
| Q2 2020 | $608,000 | +122.7% | 102,884 | 0.0% | 0.02% | +100.0% |
| Q1 2020 | $273,000 | -2.5% | 102,884 | 0.0% | 0.01% | +28.6% |
| Q4 2019 | $280,000 | – | 102,884 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Slate Path Capital LP | 7,157,601 | $3,105,683 | 0.15% |
| Artal Group S.A. | 2,779,122 | $1,206 | 0.07% |
| MFN Partners Management, LP | 3,389,215 | $1,470,580 | 0.07% |
| Intrinsic Value Partners, LLC | 43,105 | $18,703 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 115,000 | $49,899 | 0.00% |
| Penobscot Investment Management Company, Inc. | 10,000 | $4,339 | 0.00% |
| COLONY GROUP LLC | 102,884 | $44 | 0.00% |
| CAPTRUST FINANCIAL ADVISORS | 292,645 | $126,979 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 592,237 | $256,971 | 0.00% |
| STATE STREET CORP | 115,414 | $50,078 | 0.00% |